Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa

Journal of Clinical Pathology

Volumn 65, Issue 8, 2012, Pages 715-720

  Gunia, Sven ^a   Kakies, Christoph ^b   Erbersdobler, Andreas ^b   Koch, Stefan ^a   May, Matthias ^c  

^a Helios Clinics Bad Saarow   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c St Elisabeth Clinic Straubing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN; HISTONE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PHOSPHOHISTONE H3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER MUCOSA; CANCER CYTODIAGNOSIS; CANCER STAGING; CARCINOMA IN SITU; CELL NUCLEUS; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS; PATHOLOGIST; PRIORITY JOURNAL; REPRODUCIBILITY; STAINING; TISSUE SECTION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; CARCINOMA IN SITU; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; FEMALE; GERMANY; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; MUCOUS MEMBRANE; OBSERVER VARIATION; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 85027938662     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200532     Document Type: Article

References (35)

1. Montifori R, Chen L, Lopez-Beltran A, et al. Inverted (endophytic) noninvasive lesions and neoplasms of the urothelium: the cinderella group has yet to be fully exploited. Eur Urol 2011;59:225-30.
2. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001;25:1074-8. (Pubitemid 32685906)
3. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-74. (Pubitemid 29244858)
4. Wolf H, Melsen F, Pedersen SE, et al. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994;157:147-51. (Pubitemid 24205663)
5. Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584-94.
6. McKenney JK, Gomez JA, Desai S, et al. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001;25:356-62. (Pubitemid 32174205)
7. Williamson SR, Montironi R, Lopez-Beltran A, et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol 2010;76:112-26.
8. Yin M, Bastacky S, Parwani AV, et al. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol 2008;39:527-35.
9. Hodges KB, Lopez-Beltran A, Davidson DD, et al. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol 2010;41:155-62.
10. Brandau S, Böhle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 2001;39:491-7. (Pubitemid 32678962)
11. Murali R, Delprado W. CD10 immunohistochemical staining in urothelial neoplasms. Am J Clin Pathol 2005;124:371-9. (Pubitemid 41232923)
12. Gunia S, Kakies C, May M, et al. Lewis(y) antigen (blood group 8, BG8) is a useful marker in the histopathological differential diagnosis of flat urothelial lesions of the urinary bladder. J Clin Pathol 2011;64:672-6.
13. Krüger S, Müller H. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 1995;75:480-4.
14. Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011;42:455-81.
15. Emerson RE, Ulbright TM. Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol 2005;27:301-16. (Pubitemid 41803489)
16. Eble J, Sauter G, Epstein JI, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004:110-23.
17. Grignon DJ. The current classification of urothelial neoplasms. Mod Pathol 2009;22 (Suppl 2):S60-9.
18. Babjuk M, Oosterlinck W, Sylvetser R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
19. Bellmunt J, Orsola A, Wiegel T, et al. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi45-9.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
21. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol 2007;127:380-4. (Pubitemid 46806331)
22. Casper DJ, Ross KI, Messina JL, et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 2010;32:650-4.
23. Angi M, Damato B, Kalirai H, et al. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Opthalmol 2011;89:e155-60.
24. Fukushima S, Terasaki M, Sakata K, et al. Sensitivity and usefulness of antiphosphohistone- H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol 2009;26:51-7.
25. Sertel O, Catalyurek UV, Shimada H, et al. Computer-aided prognosis of neuroblastoma: detection of mitosis and karyorrhexis cells in digitized histological images. Conf Proc IEEE Eng Med Biol Soc 2009;2009:1433-6.
26. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-60. (Pubitemid 27510848)
27. Juan G, Traganos F, James WM, et al. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 1998;32:71-7. (Pubitemid 28246753)
28. Hendzel MJ, Nishioka WK, Raymond Y, et al. Chromatin condensation is not associated with apoptosis. J Biol Chem 1998;273:24470-8. (Pubitemid 28454940)
29. Scholzen T, Gerdes J. The Ki67-protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
30. Ladstein RG, Bachmann IM, Straume O, et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 2010;10:140.
31. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008;35:433-44. (Pubitemid 351519417)
32. Oxley JD, Cottrell AM, Adams S, et al. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology 2009;55:705-8.
33. Murata S, Iseki M, Kinjo M, et al. Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Am J Clin Pathol 2010;134:862-72.
34. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 2007;51:152-60. (Pubitemid 44821530)
35. Fritsche HM, Burger M, Dietmaier W, et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 2010;134:597-603.